Epigenetic modifications, such as DNA methylation, have emerged as novel and promising key areas of cancer research in a liquid biopsy with broad potential applications in early cancer detection, risk assessment, prognosis, and prediction of response to therapy.
Cell-free methylated DNA (CfDNA) immunoprecipitation and high throughput sequencing (cfMeDIP-seq) is a highly sensitive, novel technique for non-invasive cancer detection and classification via identification of tumor-specific methylation patterns in cell-free DNA (cfDNA).
CfDNA methylation profiling provides several advantages over the methods based on somatic mutations. DNA methylation is a tissue-specific and stable epigenetic mark that allows one to determine the tissue of origin. In addition, each tumor type has a specific and defined methylome profile of hypermethylation of the CpG island in tumor-suppressor genes, which distinguishes cancer tissue from healthy tissue.
Register for this webinar to hear a discussion about the applications and analysis of cfMeDIP-seq in liquid biopsy with a special interest in cancer detection.
Pier Vitale Nuzzo, MD, Ph.D., Research Fellow at Dana Farber Cancer Institute, Harvard Medical School
Pier Vitale Nuzzo received his MD and Ph.D. in Transitional Medicine in Oncology and Hematology from the University of Genoa, Italy. After completing his medical residency in Medical Oncology, he joined the Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute of Boston. He is currently a Postdoctoral Research Fellow at Dana-Farber Cancer Institute, where he is working on clinical and translational research projects in kidney and bladder cancers. Pier Vitale’s research is focused on cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), a non-invasive, cost-effective, and sensitive assay for genome-wide bisulfite-free plasma DNA methylation.Message Presenter
Sandor Spisak, Ph.D., Instructor in Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Sandor Spisak received his Ph.D. in Gastroenterology from Semmelweis University, Budapest, Hungary in 2011. His research focus was colorectal cancer development and biomarker discovery. He completed his postdoctoral training at DFCI in Boston between 2013-2020. He focused on germline genetics and epigenetics in prostate cancer using genome and epigenome editing techniques. From 2021 he was promoted to instructor at DFCI. He recently turned his research focus towards developmental biology in the intestine.Message Presenter
Who Should Attend?
- Clinical oncology and cancer researchers
- Epigenetics researchers
- DNA methylation researchers
- Stem cell researchers
- Sequencing core facilities
- Next-generation sequencing facilities
- R&D directors
- Medical science liaisons
What You Will Learn
Join this webinar to learn about:
• The advantages of CfDNA methylation profiling over methods based on somatic mutations
• How cfMeDIP-seq can be used for non-invasive cancer detection and classification
• Potential applications and analysis of cfMeDIP-seq in liquid biopsy samples
Diagenode provides complete solutions for epigenetics research in immuno-oncology, neuroscience, and more. Our comprehensive approach to gain insights into RNA, DNA, and chromatin analysis from solid tumor to liquid biopsy samples with experimentally validated, easy-to-use solutions and services give researchers the success to move from research to translational and clinical applications.
In addition, our Epigenomics Profiling Services provide epigenome-wide drug discovery, transgenerational studies, epigenetic biomarker identification including cancer biomarkers, and functional epigenomics.
Speakers from Dana-Farber Cancer Institute https://www.dana-farber.org/